Hallucinations in schizophrenia and ...
Document type :
Article dans une revue scientifique
DOI :
PMID :
Permalink :
Title :
Hallucinations in schizophrenia and Parkinson's disease: an analysis of sensory modalities involved and the repercussion on patients
Author(s) :
Llorca, Pierre-Michel [Auteur]
CHU Clermont-Ferrand
Université d'Auvergne - Clermont-Ferrand I [UdA]
Pereira, B. [Auteur]
CHU Clermont-Ferrand
Jardri, Renaud [Auteur]
Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab]
Chereau-Boudet, I. [Auteur]
CHU Clermont-Ferrand
Université d'Auvergne - Clermont-Ferrand I [UdA]
Brousse, G. [Auteur]
CHU Clermont-Ferrand
Université d'Auvergne - Clermont-Ferrand I [UdA]
Misdrahi, D. [Auteur]
Centre hospitalier Charles Perrens [Bordeaux]
Institut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
Fénelon, G. [Auteur]
Institut Mondor de Recherche Biomédicale [IMRB]
École normale supérieure - Paris [ENS-PSL]
Tronche, A.-M. [Auteur]
CHU Clermont-Ferrand
Schwan, Raymund [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Lançon, C. [Auteur]
Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants [SPMC]
Hôpital Sainte-Marguerite [CHU - APHM] [Hôpitaux Sud ]
Marques, A. [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Ulla, Miguel [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Derost, P. [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Debilly, Berangere [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Durif, Franck [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Chazeron, Ingrid De [Auteur]
Université d'Auvergne - Clermont-Ferrand I [UdA]
CHU Clermont-Ferrand
CHU Clermont-Ferrand
Université d'Auvergne - Clermont-Ferrand I [UdA]
Pereira, B. [Auteur]
CHU Clermont-Ferrand
Jardri, Renaud [Auteur]

Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab]
Chereau-Boudet, I. [Auteur]
CHU Clermont-Ferrand
Université d'Auvergne - Clermont-Ferrand I [UdA]
Brousse, G. [Auteur]
CHU Clermont-Ferrand
Université d'Auvergne - Clermont-Ferrand I [UdA]
Misdrahi, D. [Auteur]
Centre hospitalier Charles Perrens [Bordeaux]
Institut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
Fénelon, G. [Auteur]
Institut Mondor de Recherche Biomédicale [IMRB]
École normale supérieure - Paris [ENS-PSL]
Tronche, A.-M. [Auteur]
CHU Clermont-Ferrand
Schwan, Raymund [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Lançon, C. [Auteur]
Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants [SPMC]
Hôpital Sainte-Marguerite [CHU - APHM] [Hôpitaux Sud ]
Marques, A. [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Ulla, Miguel [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Derost, P. [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Debilly, Berangere [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Durif, Franck [Auteur]
Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Chazeron, Ingrid De [Auteur]
Université d'Auvergne - Clermont-Ferrand I [UdA]
CHU Clermont-Ferrand
Journal title :
Scientific reports
Abbreviated title :
Sci Rep
Volume number :
6
Pages :
38152
Publication date :
2016-12-01
ISSN :
2045-2322
HAL domain(s) :
Sciences cognitives
English abstract : [en]
Hallucinations have been described in various clinical populations, but they are neither disorder nor disease specific. In schizophrenia patients, hallucinations are hallmark symptoms and auditory ones are described as the ...
Show more >Hallucinations have been described in various clinical populations, but they are neither disorder nor disease specific. In schizophrenia patients, hallucinations are hallmark symptoms and auditory ones are described as the more frequent. In Parkinson's disease, the descriptions of hallucination modalities are sparse, but the hallucinations do tend to have less negative consequences. Our study aims to explore the phenomenology of hallucinations in both hallucinating schizophrenia patients and Parkinson's disease patients using the Psycho-Sensory hAllucinations Scale (PSAS). The main objective is to describe the phenomena of these clinical symptoms in those two specific populations. Each hallucinatory sensory modality significantly differed between Parkinson's disease and schizophrenia patients. Auditory, olfactory/gustatory and cœnesthetic hallucinations were more frequent in schizophrenia than visual hallucinations. The guardian angel item, usually not explored in schizophrenia, was described by 46% of these patients. The combination of auditory and visual hallucinations was the most frequent for both Parkinson's disease and schizophrenia. The repercussion index summing characteristics of each hallucination (frequency, duration, negative aspects, conviction, impact, control and sound intensity) was always higher for schizophrenia. A broader view including widespread characteristics and interdisciplinary works must be encouraged to better understand the complexity of the process involved in hallucinations.Show less >
Show more >Hallucinations have been described in various clinical populations, but they are neither disorder nor disease specific. In schizophrenia patients, hallucinations are hallmark symptoms and auditory ones are described as the more frequent. In Parkinson's disease, the descriptions of hallucination modalities are sparse, but the hallucinations do tend to have less negative consequences. Our study aims to explore the phenomenology of hallucinations in both hallucinating schizophrenia patients and Parkinson's disease patients using the Psycho-Sensory hAllucinations Scale (PSAS). The main objective is to describe the phenomena of these clinical symptoms in those two specific populations. Each hallucinatory sensory modality significantly differed between Parkinson's disease and schizophrenia patients. Auditory, olfactory/gustatory and cœnesthetic hallucinations were more frequent in schizophrenia than visual hallucinations. The guardian angel item, usually not explored in schizophrenia, was described by 46% of these patients. The combination of auditory and visual hallucinations was the most frequent for both Parkinson's disease and schizophrenia. The repercussion index summing characteristics of each hallucination (frequency, duration, negative aspects, conviction, impact, control and sound intensity) was always higher for schizophrenia. A broader view including widespread characteristics and interdisciplinary works must be encouraged to better understand the complexity of the process involved in hallucinations.Show less >
Language :
Anglais
Audience :
Non spécifiée
Administrative institution(s) :
Université de Lille
CNRS
CHU Lille
CNRS
CHU Lille
Research team(s) :
Équipe Psychiatrie & Croyance (PsyCHIC)
Submission date :
2019-02-13T14:48:18Z
2020-02-11T15:57:38Z
2020-03-19T12:23:37Z
2020-02-11T15:57:38Z
2020-03-19T12:23:37Z
Files
- hallucinations_schizophrenia_parkingson.pdf
- Version éditeur
- Open access
- Access the document